

Juan Carlos Doadrio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1395220/publications.pdf>

Version: 2024-02-01

24
papers

2,268
citations

331670

21
h-index

642732

23
g-index

24
all docs

24
docs citations

24
times ranked

2716
citing authors

#	ARTICLE	IF	CITATIONS
1	Multifunctional pH sensitive 3D scaffolds for treatment and prevention of bone infection. <i>Acta Biomaterialia</i> , 2018, 65, 450-461.	8.3	68
2	Antibacterial effect of antibiotic-loaded SBA-15 on biofilm formation by <i>Staphylococcus aureus</i> and <i>Staphylococcus epidermidis</i> . <i>Journal of Antibiotics</i> , 2017, 70, 259-263.	2.0	10
3	Mesoporous silica nanoparticles as a new carrier methodology in the controlled release of the active components in a polypill. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 97, 1-8.	4.0	42
4	Drug release from ordered mesoporous silicas. <i>Current Pharmaceutical Design</i> , 2015, 21, 6213-6819.	1.9	43
5	A molecular model to explain the controlled release from SBA-15 functionalized with APTES. <i>Microporous and Mesoporous Materials</i> , 2014, 195, 43-49.	4.4	41
6	Tailoring hierarchical meso- and macroporous 3D scaffolds: from nano to macro. <i>Journal of Materials Chemistry B</i> , 2014, 2, 49-58.	5.8	35
7	Usefulness of SBA-15 mesoporous ceramics as a delivery system for vancomycin, rifampicin and linezolid: a preliminary report. <i>International Journal of Antimicrobial Agents</i> , 2012, 40, 252-256.	2.5	48
8	Osteostatin-loaded onto mesoporous ceramics improves the early phase of bone regeneration in a rabbit osteopenia model. <i>Acta Biomaterialia</i> , 2012, 8, 2317-2323.	8.3	51
9	The osteoinductive properties of mesoporous silicate coated with osteostatin in a rabbit femur cavity defect model. <i>Biomaterials</i> , 2010, 31, 8564-8573.	11.4	87
10	A rational explanation of the vancomycin release from SBA-15 and its derivative by molecular modelling. <i>Microporous and Mesoporous Materials</i> , 2010, 132, 559-566.	4.4	41
11	Osteostatin-loaded bioceramics stimulate osteoblastic growth and differentiation. <i>Acta Biomaterialia</i> , 2010, 6, 797-803.	8.3	85
12	Bacterial adherence to SiO ₂ -based multifunctional bioceramics. <i>Journal of Biomedical Materials Research - Part A</i> , 2009, 89A, 215-223.	4.0	22
13	Influence of mesoporous structure type on the controlled delivery of drugs: release of ibuprofen from MCM-48, SBA-15 and functionalized SBA-15. <i>Journal of Sol-Gel Science and Technology</i> , 2009, 50, 421-429.	2.4	136
14	An optimized β -tricalcium phosphate and agarose scaffold fabrication technique. <i>Journal of Biomedical Materials Research - Part A</i> , 2008, 84A, 99-107.	4.0	42
15	Functionalization of mesoporous materials with long alkyl chains as a strategy for controlling drug delivery pattern. <i>Journal of Materials Chemistry</i> , 2006, 16, 462-466.	6.7	302
16	Long term degradation of poly(ϵ -caprolactone) films in biologically related fluids. <i>Polymer Degradation and Stability</i> , 2006, 91, 1424-1432.	5.8	134
17	Release evaluation of drugs from ordered three-dimensional silica structures. <i>European Journal of Pharmaceutical Sciences</i> , 2005, 26, 365-373.	4.0	200
18	Tissue regeneration: A new property of mesoporous materials. <i>Solid State Sciences</i> , 2005, 7, 983-989.	3.2	186

#	ARTICLE	IF	CITATIONS
19	Bioactivity and mechanical properties of SiO ₂ -CaO-P ₂ O ₅ glass-ceramics. Journal of Materials Chemistry, 2005, 15, 1353-1359.	6.7	49
20	Mesoporous SBA-15 HPLC evaluation for controlled gentamicin drug delivery. Journal of Controlled Release, 2004, 97, 125-132.	9.9	350
21	Calcium sulphate-based cements containing cephalexin. Biomaterials, 2004, 25, 2629-2635.	11.4	76
22	Hexagonal ordered mesoporous material as a matrix for the controlled release of amoxicillin. Solid State Ionics, 2004, 172, 435-439.	2.7	180
23	Preparation, characterization, and in vitro release of Ibuprofen from Al ₂ O ₃ /PLA/PMMA composites. , 1998, 39, 423-428.		34
24	Binding of Pt-pentamidine to nucleosomal DNA. Studies of the antiproliferative activity of the drug against human cancer cells. Chemico-Biological Interactions, 1993, 89, 61-72.	4.0	6